The DSEX lost 231 points on March 8 — a 4.42% single-session crash, the steepest since the coronavirus panic of March 2020. Of 390 issues traded, 371 declined. Only 10 advanced. The market shed approximately Tk 13,400 crore in capitalisation.
Square Pharmaceuticals lost Tk 1.60.
That disparity — a 0.74% decline against a 4.42% benchmark crash — is exactly the kind of outperformance defensive investors count on. Square Pharma outperformed the DSEX by 368 basis points in a session where 95% of all traded stocks fell. But the volume data tells a different story, and understanding why matters more than celebrating the headline number.
What the Numbers Actually Show
Square Pharma closed at Tk 214.50, down from Tk 216.10. The DS30 — the blue-chip index where Square Pharma carries significant weight — dropped 4.55%, slightly worse than the broad market. The Shariah index lost 3.36%. Every major index finished at or near session lows.
Here is where the defensive narrative gets complicated. Square Pharma’s trading volume on March 8 was 334,034 shares — against an average daily volume of 856,869. That is a 61% contraction in participation. When a defensive stock holds its price on dramatically lower volume, it does not necessarily mean buyers are supporting the floor. It can mean sellers have not yet decided to exit.
The pharma sector as a whole accounted for 14.6% of the day’s turnover. Large-cap pharma names — including Beximco Pharmaceuticals, Beacon Pharma, and ACI — suffered substantial price erosion. The sector was not spared. Square Pharma simply fell less.
Why the Energy Crisis Hits Pharma Too
The March 8 crash was driven by a specific catalyst: escalating US-Israel conflict with Iran, Tehran’s threat to close the Strait of Hormuz, and a near-40% surge in LNG prices. For Bangladesh — an import-dependent economy — this is not abstract geopolitics. It is a direct cost shock.
Pharmaceuticals are typically considered defensive because demand is inelastic — people do not stop buying medication in a downturn. That logic holds for revenue. It does not hold for margins.
Bangladesh’s pharma sector imports a significant share of its active pharmaceutical ingredients and raw materials. Higher energy prices raise shipping costs, production costs, and the price of imported inputs simultaneously. Square Pharma’s PE ratio of 7.55 and EPS of Tk 29.27 reflect current earnings — earnings generated under a different cost structure. If LNG prices remain elevated and the taka faces import pressure, those fundamentals compress.
This is the gap between “defensive stock” and “immune stock.” Square Pharma is the former. Nothing on the DSE is the latter.
Square Pharma’s Fundamentals at Current Levels
At Tk 214.50, Square Pharma trades at 7.55 times earnings with a dividend yield of 5.45%. Its beta of 0.75 confirms what March 8 demonstrated empirically — the stock moves less than the market in both directions. Market capitalisation stands at approximately Tk 195.91 billion, making it the pharma sector’s largest constituent by a wide margin.
The 52-week range — Tk 198.00 to Tk 249.80 — places the current price in the lower third. The stock sits 14% below its 52-week high and just 8% above its 52-week low.
For comparison, consider what happened elsewhere on the same day. BRAC Bank fell 8.42%. City Bank dropped 7.31%. BAT Bangladesh lost 6.66%. Against that carnage, Square Pharma’s 0.74% decline looks like a fortress. But fortresses can be starved if the siege lasts long enough.
What Pharma Investors Should Watch Next
The weekly picture is more revealing than the daily one. Over the week ending March 8, the DSEX fell 359 points — a 6.42% weekly decline. The DS30 lost 7.28%. These are not one-day aberrations. This is a sustained, accelerating selloff across four consecutive declining sessions.
Square Pharma’s defensive characteristics protected investors in the first wave of panic. Whether that protection holds depends on three factors: the duration of the energy price spike, the central bank’s response to import cost pressures, and whether institutional investors begin rotating out of pharma to raise cash.
The volume contraction on March 8 — 61% below average — is the metric to watch. If volume returns to normal levels and the price holds, the defensive floor is real. If volume returns and the price does not hold, March 8 was not the victory it appeared to be.
For investors evaluating whether to add Square Pharma at these levels, the PE ratio context and the broader pharma sector dynamics are essential reading. A 7.55x multiple is cheap — unless earnings are about to contract. The next quarterly results will answer that question. Until then, the market is pricing in hope, not certainty.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Stock market investments carry risk, including potential loss of principal. Consult a licensed financial advisor before making investment decisions.